US20180153827A1 - Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver - Google Patents

Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver Download PDF

Info

Publication number
US20180153827A1
US20180153827A1 US15/697,193 US201715697193A US2018153827A1 US 20180153827 A1 US20180153827 A1 US 20180153827A1 US 201715697193 A US201715697193 A US 201715697193A US 2018153827 A1 US2018153827 A1 US 2018153827A1
Authority
US
United States
Prior art keywords
liver
optionally substituted
membered ring
ring containing
hoba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/697,193
Other languages
English (en)
Inventor
John Rathmacher
Naji Abumrad
Charles Flynn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolic Technologies LLC
MTI Biotech Inc
Original Assignee
Metabolic Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Technologies LLC filed Critical Metabolic Technologies LLC
Priority to US15/697,193 priority Critical patent/US20180153827A1/en
Publication of US20180153827A1 publication Critical patent/US20180153827A1/en
Assigned to MTI BIOTECH, INC. reassignment MTI BIOTECH, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ABUMRAD, NAJI, FLYNN, CHARLES, RATHMACHER, JOHN
Priority to US18/077,832 priority patent/US12383515B2/en
Priority to US19/294,041 priority patent/US20250360094A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a composition
  • a composition comprising a ⁇ -ketoaldehyde ( ⁇ -KA) scavenging compound, such as 2-Hydroxybenzylamine (2-HOBA), and methods of administering a ⁇ -KA scavenger to treat, prevent or improve diseases or conditions relating to the liver including nonalcoholic fatty liver disease (NAFLD) and/or alcoholic liver disease (ALD), and/or nonalcoholic steatohepatits (NASH).
  • NAFLD nonalcoholic fatty liver disease
  • ALD alcoholic liver disease
  • NASH nonalcoholic steatohepatits
  • Chronic liver disease due to alcohol is a leading cause of morbidity and mortality that continues to rise.
  • Second to viral hepatitis chronic ethanol overconsumption is responsible for 25% of all deaths caused by liver cancer and cirrhosis.
  • Chronic alcohol consumption is a frequent comorbidity of liver disease and cancer.
  • the burden of health care for alcoholic liver disease (ALD) is high with cost estimates approaching $27 billion per year in the U.S. alone. Abstinence is the best therapy for ALD but recidivism is a major risk with relapse rates ranging from 67%-81% over the course of a year.
  • ALD includes a range of hepatic manifestations including fatty liver (steatosis), hepatitis and cirrhosis/fibrosis that may present simultaneously in a given individual.
  • the spectrum of ALD ranges from simple steotosis to alcoholic steatohepatitis (ASH) to cirrhosis and is aggravated with obesity.
  • ASH alcoholic steatohepatitis
  • Ethanol metabolism promotes antioxidant depletion and leads to the formation of injurious entities including acetaldehyde, acetate, reactive oxygen species (ROS), and lipid peroxides that induce inflammatory responses.
  • ROS reactive oxygen species
  • alcohol and its metabolites incite inflammation by promoting gut leakiness and stimulating immune cells (the so-called adaptive immune response) and/or activating innate immune pathways, such as complement. While activation of innate immunity components initiates alcoholic liver injury it also triggers hepatoprotective, regenerative, and anti-inflammatory responses that reduce hepatocyte damage.
  • lipid peroxidation and oxidative stress play significant roles in inflammation and the pathogenesis of chronic liver disease, especially ALD.
  • Aldehydes such as malondialdehyde (MDA) and 4-hydroxynonenol (4-HNE) form covalent protein adducts which interfere with normal protein function.
  • MDA malondialdehyde
  • 4-HNE 4-hydroxynonenol
  • ⁇ -KAs also known as isolevuglandins or isoketals
  • FIG. 1 ⁇ -KAs adduct rapidly and covalently to proteins and DNA, interfere with normal molecule function, and form protein-protein cross-links (isoketals).
  • ⁇ -KAs are produced by the F 2 -Isoprostane (F 2 -IsoP) pathway.
  • the ⁇ -KAs have been shown to accumulate in various pathophysiological conditions through the non-classic eicosanoids, isoprostanes (IsoP) and isofurans (IsoF) that are formed non-enzymatically by free radical mediated peroxidation of arachidonic acid.
  • Isofurans are similar to the isoprostanes, but contain a substituted tetrahydrofuran ring. It has been demonstrated that anti- ⁇ -KA antibody titers in the serum of human subjects with ALD are elevated relative to subjects without ALD ( FIG. 2 ).
  • ALD is characterized by the development of steatosis, inflammation, hepatocyte necrosis and apoptosis, with the eventual development of fibrosis and cirrhosis. It is also well established that consumption of alcohol in excess causes an oxidative injury to the liver. F 2 -IsoPs have been shown to be the most accurate predictors of oxidative stress in vivo, and their levels are increased in alcoholic liver disease, and chronic hepatitis. Over-production of KAs is implicated in the pathogenesis of several chronic inflammatory diseases. More recently, ethanol feeding in the mouse has been shown to induce formation of hepatic ⁇ -KAs which readily bind to proteins to form stable adducts. These ⁇ -KA-protein adducts are likely to contribute to ethanol-induced liver injury by eliciting proinflammatory responses or adduct-specific immune responses.
  • 2-hydroxy-benzylamine (2-HOBA), a staple of buckwheat, was found to be a potent scavenger of ⁇ -KAs scavenging ⁇ -KAs 980-fold faster than the rate of formation of ⁇ -KA-lysyl-protein adducts. Importantly, they showed that this ⁇ -KA scavenger does not inhibit cyclooxygenase enzymes.
  • 2-HOBA In a model of oxidant mediated cell death ( FIG. 3 ), 2-HOBA almost completely prevented cell death induced by t-butylhydroperoxide (tBHP).
  • tBHP t-butylhydroperoxide
  • 2-HOBA has a protective effect against oxidant mediated cell death HepG2 cells exposed to varying concentrations of hydrogen peroxide (H 2 O 2 ).
  • ALD Advanced laser desorption deposition
  • Current therapeutic modalities for ALD include corticosteroids and pentoxyfilline. Corticosteroids improve short-term survival of severe forms of alcoholic hepatitis, but are frequently contraindicated. Pentoxyfilline, a competitive non-selective phosphodiesterase inhibitor, improved short-term survival in severe acute alcoholic hepatitis and demonstrated improved risk-benefit profiles compared to prednisone, but when combined with prednisone it did not confer additional benefit.
  • the trapping of toxic oxidized lipids by 2-HOBA is novel in that it attenuates the formation of aggravating protein adducts that sustain inflammation and drive liver injury.
  • the present invention includes use of 2-HOBA for preventing ALD and also attenuating the propagation of alcoholic liver disease.
  • NASH nonalcoholic fatty liver disease
  • NASH nonalcoholic steatohepatits
  • ROS reactive oxygen species
  • RLS reactive lipid species
  • NASH is the inflammatory form of NAFLD and is characterized by excess liver fat, inflammation, and hepatocellular ballooning with or without fibrosis. NASH is most concerning for progression to end stage liver disease, or cirrhosis. The mechanisms and conditions favoring NASH are unclear but histologically, it bears resemblance to alcoholic steatohepatitis.
  • BFEs bifunctional electrophiles
  • ROS reactive oxygen species
  • MDA malondialdehyde
  • MGO methylglyoxal
  • LGs levuglandins
  • Nonalcoholic steatohepatitis is liver inflammation and damage caused by a buildup of fat in the liver. NASH resembles ALD but occurs in people who consume little or no alcohol. NASH affects two to five percent of Americans, most often in people who are middle-aged and overweight or obese.
  • the present invention includes use of 2-HOBA for preventing and/or treating NASH.
  • the present invention includes use of 2-HOBA to scavenge toxic oxidized lipids (ketoaldehydes) to effectively regulate the inflammatory program and lead to reversal in the associated hepatic injury.
  • the present invention includes use of 2-HOBA to target ⁇ -KA to prevent lipid peroxidation and the resulting ⁇ -KA-specific immune responses in alcoholic liver disease.
  • FIG. 1 is a graphic depicting how ⁇ -KAs react with lysine or other primary amines to form a reversible Schiff base adducts.
  • FIG. 2 is a graph depicting serum ⁇ -KA antibody titers in hospitalized ICU patients with and without alcoholic liver disease.
  • FIG. 3 is a graph depicting the protective effect of 2-HOBA against oxidant mediated cell death in mouse hepatocytes increasing t-butylhydroperoxide.
  • FIG. 4A depicts ROS is HepaRG with increasing ethanol dose and FIG. 4B depicts the protective effect of 2-HOBA with increasing ethanol concentration.
  • FIG. 5A depicts ALT and FIG. 5B depicts AST levels in the media of HepaRG cells pretreated with different levels of 2-HOBA.
  • FIG. 6 shows the effects of 2-HOBA pretreatment against ethanol-mediated ⁇ -KA formation.
  • FIG. 7A shows the identification of ⁇ -KA-modified histone-H3 and -H4 in mouse lung and FIG. 7B shows an immunoblot of isolated histones.
  • FIG. 8A is a graph depicting liver isoprostanes (IsoP) in mice where the efficacy of 2-HOBA was tested.
  • FIG. 8B is a graph depicting liver isofurans (IsoF) in mice where the efficacy of 2-HOB was tested.
  • FIG. 8C is a graph depicting kidney isoprostanes (IsoP) in mice where the efficacy of 2-HOBA was tested.
  • FIG. 8D is a graph depicting kidney isofurans (IsoF) in mic where the efficacy of 2-HOBA was tested.
  • FIG. 9A depicts IsoLG formation in the livers of mice fed a high fat diet.
  • FIG. 9B shows IsoLG staining on normal livers.
  • FIG. 9C depicts IsoLG staining on steatosis livers.
  • FIG. 9D shows IsoLG staining on NASH livers.
  • FIG. 10A depicts neutrophil staining in NASH human liver.
  • FIG. 10B is a graph showing MPO-positive cells in NASH livers compared to normal or SS specimens.
  • FIG. 11A depicts the progression of NAFLD in the STAM model.
  • FIG. 11B shows body weight over time in normal and streptozotocin-injected mice fed high fat diet for 16 weeks.
  • FIG. 11C shows ALT elevation in control and STAM mice.
  • FIG. 11D shows glucose elevation in control and STAM mice.
  • FIG. 11E shows insulin reduction in control and STAM mice.
  • FIG. 11F shows a table of individual NAS components and NAFLD activity scores in control and STAM mice.
  • FIG. 11G shows representative livers and liver sections stained with H&E or Trichrome blue.
  • FIG. 11H shows hepatocyte ballooning, inflammation and TUNEL-positive apoptotic bodies.
  • FIG. 11I shows f4/80 positive macrophage content in control compared to STAM mice.
  • FIGS. 12A-12T compare the effects of administering 2-HOBA to STAM mice v. control mice.
  • FIG. 12A shows body weight change over time in STAM mice.
  • FIG. 12B shows liver weight.
  • FIG. 12C shows liver-to-body-weight ratio.
  • FIG. 12D shows hepatic 2-HOBA content.
  • FIG. 12E shows plasma glucose comparisons.
  • FIG. 12F shows insulin comparisons;
  • FIG. 12G shows serum IsoProstanes comparisons.
  • FIG. 12H demonstrates representative livers and liver sections stained with H&E, trichrome blue and Picosirius Red.
  • FIG. 12I shows serum ALT
  • FIG. 12J shows cholesterol
  • FIG. 12K shows tricglycerides.
  • FIGS. 12M-12T show gRT-PCR measurements of key genes in hepatic nutrient handling.
  • FIG. 13A-F shows insulin signaling and hepatic inflammasomes in STAMTM mice.
  • FIG. 13A shows pathways in insulin signaling.
  • FIG. 13B shows immunoblots of total liver protein from control and 2-HOBA treated STAM mice.
  • FIG. 13C shows pAKT Ser473/total AKT ratio.
  • FIG. 13D shows pGSK3 ⁇ Ser9/total pGSK3 ⁇ ratio.
  • FIG. 13E shows pmTOR pSer 2448/total mTOR ratio.
  • FIG. 13 F shows pThr202/Tyr204 pERK/total ERK ratio.
  • FIG. 14A-H depicts the development of NAFLD in DIAMONDTM mice.
  • 14 A shows the progression of NAFLD in the DIAMOND model where B6/129 mice were fed a chow diet (CD) with normal water (NW) or high fat Western Diet (WD) with high fructose/glucose (SW) for up to 52 weeks.
  • FIG. 14B shows body weight change over time
  • FIG. 14C shows liver weight
  • FIG. 14F shows representative liver sections stained with H&E (top 2 rows) or Picosirius Red (bottom 2 rows.
  • FIG. 14G shows hepatocyte ballooning, CK-18 stained ballooning, inflammation and apoptotic bodies.
  • FIG. 14H shows a table of components and NAFLD Activity Score
  • FIG. 15A-K summarizes results of DIAMONDTM mice testing.
  • FIGS. 14A-B are photos of DIAMOND mice at 28 weeks of age.
  • FIG. 14C is a photo of a DIAMOND mouse after consuming 2-HOBA for 20 weeks.
  • FIG. 14D shows an MRI if a mouse after 8 weeks of western diet feeding and 14 E shows an MRI of a mouse after 8 weeks of western diet feeding and 2-HOBA consumption.
  • FIG. 14F shows average weekly food intake and
  • FIG. 14G shows average weekly body weight of DIAMOND mice with and without 2-HOBA supplementation.
  • FIG. 14H shows mean liver/body weight ratio
  • FIG. 14I shows liver weight
  • FIG. 14J shows kidney weight
  • FIG. 14K shows pancreas weight of DIAMOND mice fed Western Diet (controls) or Western Diet with 2-HOBA (1 g/L) in drinking water for 20 wks.
  • FIG. 16A-M summarizes results of DIAMONDTM mice testing.
  • FIG. 16A shows DIAMOND mouse liver at 28 wks of age after high fructose/glucose, high fat Western Diet feeding for 20 wks (control) or FIG. 16B with 2-HOBA (1 g/L) in drinking water for 20 wks.
  • Serum ALT FIG. 16H
  • AST FIG.
  • FIG. 16I Liver steatosis ( FIG. 16J ), ballooning ( FIG. 16K ), inflammation ( FIG. 16L ), and composite NAFLD activity score ( FIG. 16M ) and fibrosis score ( FIG. 16N ) in control and 2-HOBA treated DIAMOND mice.
  • the present invention includes a novel nutritional therapy that will reduce liver injury by preventing the formation of ⁇ -KA-protein adducts and differential effects on innate and adaptive immune responses.
  • This nutritional therapy can be used to treat, prevent or improve conditions or diseases relating to the liver including but not limited to NAFLD, ALD and NASH.
  • the nutritional therapy can be used to improve overall liver health and support healthy liver function.
  • the present invention comprises a means to specifically prevent the formation of ⁇ -KA -adducts in the liver using a class of bifunctional electrophile (BFE) “scavenger” molecules.
  • BFE bifunctional electrophile
  • a series of phenolic amines that includes pyridoxamine and its water soluble derivative 2-hydroxybenzylamine (2-HOBA), a natural product of buckwheat seed comprise the preferred embodiment.
  • 2-HOBA in particular reacts 980-fold faster with ⁇ -KAs than with lysine, preventing protein and lipid adduction in vitro and in vivo.
  • compositions and methods of this invention are directed to animals, including human and non-human animals.
  • the animal may be healthy or may be suffering from a disease or condition.
  • administering or administration includes providing a composition to a mammal, consuming the composition and combinations thereof.
  • the present invention includes compositions and methods of use of 2-HOBA, alternatively named salicylamine, SAM, 2-hydroxylbenzylamine, and pentylpyridoxamine (PPM).
  • 2-HOBA alternatively named salicylamine, SAM, 2-hydroxylbenzylamine, and pentylpyridoxamine (PPM).
  • Embodiments of the present invention include compounds of the following formula, and their use as agents in a method for treating, preventing, or ameliorating liver conditions or diseases including NAFLD, ALD and NASH to a subject with or at risk of liver conditions or diseases including NAFLD, ALD and NASH, thereby inhibiting or treating the liver conditions or diseases:
  • R is N or C
  • R 2 is independently H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 2 , R 3 and R 4 , and may cyclize with to one or more R 2 , R 3 , or R 5 to form an optionally substituted C 3-8 membered ring containing C, O, S or N;
  • R 3 is H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 , R 2 and R 3 may cyclize with to one or more R 2 or R 5 to form an optionally substituted C 3-8 membered ring containing C, O, S or N;
  • R 4 is H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 , R 2 and R 3 may cyclize with to one or more R 2 , R 3 , or R 5 to form an optionally substituted C 3-8 membered ring containing C, O, S or N;
  • R 5 is a bond, H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 , R 2 and R 3 may cyclize with to one or more R 2 , R 3 , or R 4 to form an optionally substituted C 3-8 membered ring containing C, O, S or N;
  • Another embodiment of the present invention includes compounds of the following formula, and their use in methods for treating, preventing, or ameliorating liver conditions or diseases including NAFLD, ALD and NASH to a subject with or at risk of these liver conditions:
  • R is N or C
  • R 2 is independently H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 2 , R 3 and R 4 , and may cyclize with to one or more R 2 , R 3 , or R 5 to form an optionally substituted C 3-8 membered ring containing C, O, S or N;
  • R 3 is H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 , R 2 and R 3 may cyclize with to one or more R 2 or R 5 to form an optionally substituted C 3-8 membered ring containing C, O, S or N;
  • R 4 is H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 , R 2 and R 3 may cyclize with to one or more R 2 , R 3 , or R 5 to form an optionally substituted C 3-8 membered ring containing C, O, S or N;
  • R 5 is a bond, H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 , R 2 and R 3 may cyclize with to one or more R 2 , R 3 , or R 4 to form an optionally substituted C 3-8 membered ring containing C, O, S or N; and stereoisomers and analogs thereof.
  • the compound may be selected from the compounds disclosed herein.
  • the compound may be salicylamine.
  • Another embodiment of the present invention is a method for treating, preventing, or ameliorating liver conditions or diseases including NAFLD, ALD and NASH to a subject with or at risk of liver conditions or diseases including NAFLD, ALD and NASH, thereby inhibiting or treating the liver conditions, comprising the step of co-administering to the subject at least one compound in a dosage and amount effective to treat the dysfunction in the mammal, the compound having a structure represented by a compound of the following formula:
  • R is N or C
  • R 2 is independently H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 2 , R 3 and R 4 , and may cyclize with to one or more R 2 , R 3 , or R 5 to form an optionally substituted C 3-8 membered ring containing C, O, S or N;
  • R 3 is H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3 -8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 , R 2 and R 3 may cyclize with to one or more R 2 or R 5 to form an optionally substituted C 3-8 membered ring containing C, O, S or N;
  • R 4 is H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 , R 2 and R 3 may cyclize with to one or more R 2 , R 3 , or R 5 to form an optionally substituted C 3-8 membered ring containing C, O, S or N;
  • R 5 is a bond, H, hydroxy, halogen, nitro, CF 3 , C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 , R 2 and R 3 may cyclize with to one or more R 2 , R 3 , or R 4 to form an optionally substituted C 3-8 membered ring containing C, O, S or N; and stereoisomers and analogs thereof; with a drug having a known side effect of treating, preventing, or ameliorating liver conditions or diseases including NAFLD, ALD and NASH.
  • Examples of compounds that may be used with the methods disclosed herein include, but are not limited to, compounds selected from the formula:
  • R is N or C
  • R 2 is independently H, substituted or unsubstituted alkyl;
  • R 3 is H, halogen, alkoxy, hydroxyl, nitro;
  • R 4 is H, substituted or unsubstituted alkyl, carboxyl; and pharmaceutically acceptable salts thereof.
  • the compound is salicylamine (2-hydroxybenzylamine or 2-HOBA).
  • the compound may be chosen from:
  • the compound may also be chosen from:
  • the compounds or analogs may also be chosen from:
  • the compounds may also be chosen from:
  • the compounds may also be chosen from
  • the compounds of the present invention can be administered by any method and such methods are well known to those skilled in the art and include, but are not limited to oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration, intraaural administration, intracerebral administration, rectal administration, and parenteral administration, including injectable administration such as intravenous administration, intra-arterial administration, intramuscular administration and subcutaneous administration.
  • the compounds can be administered therapeutically, to treat an existing disease or condition, or prophylactically for the prevention of a disease or condition.
  • composition is combined with a suitable pharmaceutical carrier, such as dextrose or sucrose.
  • Methods of calculating the frequency by which the composition is administered are well-known in the art and any suitable frequency of administration can be used within the context of the present invention (e.g., one 6 g dose per day or two 3 g doses per day) and over any suitable time period (e.g., a single dose can be administered over a five minute time period or over a one hour time period, or, alternatively, multiple doses can be administered over an extended time period).
  • the composition of the present invention can be administered over an extended period of time, such as weeks, months or years.
  • the composition can be administered in individual servings comprising one or more than one doses (individual servings) per day, to make a daily serving comprising the total amount of the composition administered in a day or 24 hour period.
  • Any suitable dose of the present composition can be used within the context of the present invention. Methods of calculating proper doses are well known in the art.
  • Treatment refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder.
  • This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder.
  • this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.
  • HepaRG hepatocytes Fully-differentiated, 21-day, HepaRG hepatocytes (Bio-Predict International) display clear epithelial cells surrounded by hepatocyte colonies that contain numerous bile canaliculi which readily metabolize the fluorescent MRP2 substrate, CDFDA. HepaRG cells are a unique and well-established human hepatic cell culture system with high fidelity to the absorption, distribution, metabolism, and excretion of human liver. Consistent with the known mechanisms of action of 2-HOBA, a 24 hr pre-treatment of HepaRG cells with 2-HOBA (0, 250, 500 and 1000 ⁇ M) was followed by increasing ethanol concentration (0-200 mM; 24 hr) but did not affect reactive oxygen species formation ( FIG. 4A ).
  • the present inventors investigated the identity of proteins adducted endogenously using cultured HepaRG hepatocytes, exposed to ethanol with or without prior 2-HOBA pretreatment (0, 250 or 500 ⁇ M for 24 hr.). Cells were harvested and total protein was resolved by SDS-PAGE then probed with a well-characterized single chain antibody, D11 SCFv, which recognizes peptides and proteins modified by ⁇ -KAs isomers ( FIG. 6 ).
  • ⁇ -KAs are major mediators of liver injury caused by lipid peroxidation, and that the use of 2-HOBA protects against cell death induced by such oxidants or ethanol exposure.
  • Targeting ⁇ -KAs may be used as a method for preventing lipid peroxidation and the resulting ⁇ -KA-specific immune responses in alcoholic liver disease.
  • 2-HOBA and ethanol were concurrently administered to C57/BL6J mice to establish the efficacy of 2-HOBA in mitigating ethanol-mediated liver dysfunction (increased AST and ALT), reducing ⁇ -KA formation, favorably altering immune responses and stimulating beneficial intracellular signaling pathways.
  • 2-HOBA 1.0 mg/ml
  • liver injury elevated ⁇ -KAs and liver function enzymes
  • 2-HOBA (0.5 g/L in Lieber-DeCarli liquid diet, LDLD) was administered to mice prior to ethanol treatment for 14 days to examine 2-HOBA efficacy in mitigating liver injury.
  • Ethanol (5% v/v) was administered using the NIAAA model (10 days ethanol in LDLD+binge).
  • Food intake and body weight were not significantly impacted with the addition of 0.5 g/L of 2-HOBA to LDLD (data not shown).
  • White blood cell and lymphocyte cell counts were reduced while eosinophil and basophil counts were increased with ethanol relative to maltodextrin feeding (Table 1), consistent with other reports of alcoholic liver injury. Such responses were not observed in the presence of 2-HOBA.
  • 2-HOBA at 0.5 g/L did not attenuate increases in serum AST or ALT in these studies (Table 2).
  • AST serum aspartate aminotransferase
  • ALT alanine aminotransferase
  • N 12 mice per group. **P indicates significance ⁇ 0.01, ***P indicates significance ⁇ 0.001 by unpaired Student's two-tailed t-test.
  • AST and ALT are in U/L.
  • An additional cohort of mice were administered a 14-day pretreatment of 2-HOBA (1.0 g/L) prior to administration of ethanol using the NIAAA model. Mice administered ethanol consumed less food and consequently weighed ⁇ 2.5 g less than maltodextrin-fed controls at the end of study.
  • AST serum aspartate aminotransferase
  • ALT alanine aminotransferase
  • N 12 mice per group.
  • ***P indicates significance ⁇ 0.001 by unpaired Student's two-tailed t-test.
  • AST and ALT concentrations are in U/L.
  • Blood urea nitrogen (BUN) and creatinine (CRE) units are mg/dL.
  • AST was lower in mice pretreated with 2-HOBA+ETOH (676.6 ⁇ 86.7 U/L) compared to controls (906.1 ⁇ 186.1 U/L) but these did not reach statistical significance.
  • Pre-treatment with 2-HOBA for 14 days at 1.0 g/L in the NIAAA model reduced liver injury and ameliorated the significant increases in hepatic isoprostane and isofuran content observed with ETOH exposure and additionally decreased kidney isoprostane formation.
  • F 2 -Isoprostanes are prostaglandin-like compounds formed in vivo via a non-enzymatic mechanism involving the free radical-initiated peroxidation of arachidonic acid and have been shown to be the most accurate predictors of oxidative stress in vivo. Elevated levels of plasma or urinary F 2 -IsoPs have been reported in alcoholic liver disease patients and in animals with NAFLD/NASH and increased liver F 2 -IsoP also have been reported in humans and animals with NASH. F 2 -IsoPs values are also increased in chronic hepatitis.
  • Inflammasomes are multimeric protein complexes of the innate immune system that upon PAMP (pathogen-associated molecular pattern) or DAMP (damage-associated molecular pattern) binding, either directly or through the adaptor molecule ASC, activating caspase 1. Caspase 1 in turn activates downstream signaling pathways and the resultant changes in biological function vary considerably depending upon cell type and initiating ligand. Inflammasomes are activated by members of the (NOD)-like receptor (NLR) family (NLRP1-3, NLRP6-7, NLRP12, NLRC4), NAIP and Aim2.
  • NOD NOD-like receptor
  • NLRP3 inflammasome Activation of the NLRP3 inflammasome leads to caspase-1 cleavage of inactive pro-IL-1 ⁇ , pro-IL-18 and pro-IL-33 into their active forms.
  • Fatty acids, cholesterol, and protein aggregates are among the known NLRP3-inflammasome activators.
  • the described molecular triggers of NASH inflammasomes include DNA, saturated fatty acids and LPS, NLRP-1. This suggests that IsoLGs are also additional potent inflammasome activators through mechanisms that are not fully delineated.
  • defective NLRP1- and NLRP3-signaling/activation by IsoLG ligands may underpin altered liver immunometabolism, host gut microbiome adaptations, and defective NLRP-inflammasome sensing that are hallmark of the NAFL to NASH transition.
  • 2-Hydroxybenzylamine (2-HOBA) is 980 times more reactive than lysine with ⁇ KAs and importantly, does not inhibit cyclooxygenase enzymes.
  • 2-HOBA In a model of oxidant mediated cell death 2-HOBA almost completely prevented hepatocyte cell death induced by t-butylhydroperoxide (tBHP). This is a remarkable finding given the fact the pathogenesis of oxidative injury is quite complex and multifaceted.
  • tBHP t-butylhydroperoxide
  • 2-HOBA has a protective effect against oxidant mediated cell death in HepG2 cells exposed to varying concentrations of H 2 O 2 .
  • STAM model One model used in studying the pathogenesis of NASH, cirrhosis and HCC is the STAM model, (Stelic Inc. Tokyo, Japan). With strong fidelity to human NASH both histologically and physiologically (elevated fasting blood sugar, liver biochemistries, intrahepatic lipid, dyslipidemia; FIG. 11 ), the STAM model develops the features previously difficult to obtain in genetic knockouts or dietary models of NAFLD. The present inventors have demonstrated that 2-HOBA can reduce NAFLD severity in STAM mice ( FIG. 12 ).
  • NASH is induced in C57BL/6 mice by a single subcutaneous injection of 200 ⁇ g streptozotocin (STX) solution 2 days after birth and feeding with high-fat diet beginning at 4 wks of age.
  • STX streptozotocin
  • Mice in the 2-HOBA group received 2-HOBA in drinking water (1 g/L water), while the vehicle control group received plain water without 2-HOBA.
  • All mice were placed on ad libitum high fat diet.
  • mice remained on the high fat diet and received 2-HOBA-supplemented or plain water based on their group assignment throughout the study protocol. Body weights and food/water intake were monitored weekly. Animals were sacrificed at 9 wks of age (6 weeks of 2-HOBA or vehicle treatment), and tissues and serum were collected for analysis.
  • Serum levels of glucose, insulin, alanine transaminase, aspartate transaminase, triglycerides, cholesterol, and F 2 -isoprostanes were measured. Serum and tissue levels of the following inflammatory markers were measured by multiplex assay (Luminex, Millipore, Billerica, Mass.): IL-1 ⁇ , IL-6, IL-1 ⁇ , IL-10, IL-17, MCP-1, and TNF ⁇ . Liver 2-HOBA, F 2 -isoprostane, and isofuran levels were determined by LC/MS/MS methods.
  • the livers from STAM mice were subjected to immunoblot analysis to better understand the basis for the improvements in liver function and phenotypes described in FIG. 13 .
  • 2-HOBA treatment dramatically increased AKT and GSK3 ⁇ phosphorylation without significantly altering signaling through mTOR, ERK or FOXO1.
  • the data show significantly decreased expression of pyruvate dehydrogenase kinase 4 (pdk4), a key protein in the regulation of mitochondrial fuel metabolism, suggesting that the reductions in liver weight, improvements in NASH severity and reductions in serum isoprostanes with 2-HOBA treatment may be mediated by an ⁇ KA-mediated mechanism affecting mitochondria function.
  • the data show a decrease NALP1 with 2HOBA treatment. A role for NRLP3-inflammasomes in regulating mitochondrial function was recently described.
  • DIAMOND Diet Induced Animal Model of Non-alcoholic fatty liver Disease
  • DIAMOND mice Diet Induced Animal Model of Non-alcoholic fatty liver Disease
  • the DIAMOND mouse model is unique in that it is the only murine model of NAFLD/NASH that develops NASH solely as a result of the Western diet (high fat, sugar water) with no gene knockouts or toxins to induce liver pathology ( FIG. 14 ).
  • mice Twelve 8-wk old male DIAMOND mice were placed on ad libitum high fat diet (Harlan-ENVIGO TD.88317) and water containing glucose (18.9% w/v) and fructose (23.1% w/v); all mice remained on this diet throughout the study protocol.
  • 2-HOBA 2-HOBA
  • Animals in the 2-HOBA group received 2-HOBA in drinking water (1 g/L water with glucose and fructose).
  • the vehicle control group received water without 2-HOBA (with glucose and fructose). Body weight and food intake were measured weekly.
  • GTT glucose tolerance test
  • animals were fasted for 12 hours and then glucose (2 g/kg bw of a 100 mg/mL glucose in sterile water) was administered by oral gavage. Blood was sampled at 0, 15, 30, 45, 60, 90, and 120 minutes after glucose administration and area under the curve was calculated. Animals were sacrificed at 24 wks of age (12 weeks of 2-HOBA or vehicle treatment). Tissues and serum were collected for analysis.
  • hematoxylin and eosin for scoring of steatosis, hepatocyte ballooning, and inflammation
  • Liver mRNA expression was assessed via RT-qPCR for the following genes: Tnfa, Nlrp1a, Il1b, Il18, Timp1, Col1a1, ProCard, Nlrp3, Casp1, ProIl1b, Tgfb1, Bambi, Pdk4, and Gapdh.
  • FIGS. 15-16 summarizes the results of the DIAMOND mice testing. These data demonstrate a trend for a reduction in liver weight which was accompanied a significant reduction in the liver enzymes ALT and AST with 2HOBA supplementation. These findings support the efficacy of 2-HOBA to prevent the development or attenuate the severity of NASH.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pediatric Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
US15/697,193 2016-09-06 2017-09-06 Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver Abandoned US20180153827A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US15/697,193 US20180153827A1 (en) 2016-09-06 2017-09-06 Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver
US18/077,832 US12383515B2 (en) 2016-09-06 2022-12-08 Compositions and methods of use of γ-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver
US19/294,041 US20250360094A1 (en) 2016-09-06 2025-08-07 Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383895P 2016-09-06 2016-09-06
US201662410133P 2016-10-19 2016-10-19
US15/697,193 US20180153827A1 (en) 2016-09-06 2017-09-06 Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/077,832 Continuation US12383515B2 (en) 2016-09-06 2022-12-08 Compositions and methods of use of γ-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver

Publications (1)

Publication Number Publication Date
US20180153827A1 true US20180153827A1 (en) 2018-06-07

Family

ID=61562136

Family Applications (3)

Application Number Title Priority Date Filing Date
US15/697,193 Abandoned US20180153827A1 (en) 2016-09-06 2017-09-06 Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver
US18/077,832 Active 2037-09-06 US12383515B2 (en) 2016-09-06 2022-12-08 Compositions and methods of use of γ-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver
US19/294,041 Pending US20250360094A1 (en) 2016-09-06 2025-08-07 Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver

Family Applications After (2)

Application Number Title Priority Date Filing Date
US18/077,832 Active 2037-09-06 US12383515B2 (en) 2016-09-06 2022-12-08 Compositions and methods of use of γ-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver
US19/294,041 Pending US20250360094A1 (en) 2016-09-06 2025-08-07 Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver

Country Status (8)

Country Link
US (3) US20180153827A1 (enExample)
EP (1) EP3510014A4 (enExample)
JP (3) JP7189127B2 (enExample)
CN (2) CN110177771B (enExample)
AU (1) AU2017324935B2 (enExample)
CA (1) CA3035897A1 (enExample)
MX (1) MX2019002579A (enExample)
WO (1) WO2018048932A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018201074A1 (en) * 2017-04-27 2018-11-01 Vanderbilt University Methods for treating atherosclerosis with gamma-ketoaldehyde scavengers
MX2020002441A (es) * 2017-09-05 2020-09-03 Mti Biotech Inc Composiciones y metodos de uso de depuradores de gammacetoaldehido para tratar, prevenir o mejorar fibrosis del higado.
EP3914359B1 (en) * 2019-01-25 2025-03-26 MTI Biotech, Inc. Triphenylphosphonium-tethered salicylamine derivatives
CN114344448A (zh) * 2022-01-20 2022-04-15 广西医科大学第一附属医院 Pmx-53多肽在制备治疗非酒精性脂肪性肝炎药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140256774A1 (en) * 2011-07-12 2014-09-11 Vanderbilt University Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023063A2 (en) * 1998-10-22 2000-04-27 University Of South Carolina Methods for inhibiting diabetic complications
CA2369560C (en) * 1999-04-27 2011-02-01 Makoto Nakamuta Agent for prophylaxis and treatment of liver disease
CN1628650A (zh) * 2003-12-19 2005-06-22 刘力 复方二氯醋酸二异丙胺冻干粉针制剂及其制备方法
US8822542B2 (en) * 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
WO2008070778A2 (en) * 2006-12-06 2008-06-12 Nephrogenex Inc. Pyridoxamine and low molecular weight heparinoids for diabetic kidney disease
EP2281557A4 (en) 2008-04-29 2011-08-31 Hanall Biopharma Co Ltd PHARMACEUTICAL FORMULATION CONTAINING AN ANGIOTENSIN II RECEPTOR BLOCKING AGENT
US20150087660A1 (en) * 2012-05-10 2015-03-26 Mahesh Kandula Compositions and methods for the treatment of chronic diseases and inflammatory disorders
US20150265584A1 (en) * 2014-03-18 2015-09-24 Vanderbilt University Levuglandin adducts histone h4 in a cyclooxygenase-2-dependent manner, altering its interaction with dna
JP2017537149A (ja) * 2014-11-11 2017-12-14 ヴァンダービルト ユニバーシティー 急性腎傷害を制限するための方法
WO2017033119A1 (en) * 2015-08-25 2017-03-02 Rao M Surya Compositions and methods for the treatment of liver metabolic diseases
US20210023032A1 (en) * 2017-09-05 2021-01-28 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver
MX2020002441A (es) * 2017-09-05 2020-09-03 Mti Biotech Inc Composiciones y metodos de uso de depuradores de gammacetoaldehido para tratar, prevenir o mejorar fibrosis del higado.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140256774A1 (en) * 2011-07-12 2014-09-11 Vanderbilt University Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Amarnath et al. Chem. Res. Toxicol. 2004, 17, 410-415 *
Dancygier Clinical Hepatology. Principles and Practice of Hepatobiliary Diseases, volume 2, Springer-Verlag, Berlin 2010 *
Davies et al. Curr. Pharmacol. Rep. 2017, 3 (2), 51-67 *
Definition of prevent, Princeton University "About WordNet." WordNet. Princeton University. 2010. <http://wordnet.princeton.edu>, accessed 18 September 2012 *
Longato et al. UEG Week 2014 Poster Presentation, October 20, 2014, in United European Gastroenterology Journal 2014, 2 (1S), page A136, poster P0018 *
Longato UEG Week 2014 Poster Presentation, October 20, 2014, in United European Gastroenterology Journal 2014, 2 (1S), page A136, poster P0018, cited in PTO-892 of 20 September 2018 *
Roychowdhury Free Radical Biology & Medicine 2009, 47 (11), 1526-1538, cited in IDS *
Vishnubhotla et al. World J. Hepatol. 2016, 8(20), 827-837 *
Washington et al. Human Pathology 2000, 31 (7), 822-828 *
Washington Human Pathology 2000, 31 (7), 822-828, cited in PTO-892 of 20 September 2018 *

Also Published As

Publication number Publication date
EP3510014A4 (en) 2020-05-20
AU2017324935B2 (en) 2021-10-21
AU2017324935A1 (en) 2019-03-28
MX2019002579A (es) 2020-02-05
CN110177771B (zh) 2022-12-13
CA3035897A1 (en) 2018-03-15
JP7189127B2 (ja) 2022-12-13
JP2023022236A (ja) 2023-02-14
US20230181494A1 (en) 2023-06-15
WO2018048932A1 (en) 2018-03-15
JP2019526598A (ja) 2019-09-19
CN110177771A (zh) 2019-08-27
US12383515B2 (en) 2025-08-12
EP3510014A1 (en) 2019-07-17
CN119345198A (zh) 2025-01-24
BR112019004404A2 (pt) 2019-05-28
US20250360094A1 (en) 2025-11-27
JP2025032245A (ja) 2025-03-11

Similar Documents

Publication Publication Date Title
US12383515B2 (en) Compositions and methods of use of γ-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver
Gomaa et al. Polyphenol-rich Boswellia serrata gum prevents cognitive impairment and insulin resistance of diabetic rats through inhibition of GSK3β activity, oxidative stress and pro-inflammatory cytokines
Rinwa et al. Piperine potentiates the protective effects of curcumin against chronic unpredictable stress-induced cognitive impairment and oxidative damage in mice
Yu et al. Fibroblast growth factor 21 protects mouse brain against D-galactose induced aging via suppression of oxidative stress response and advanced glycation end products formation
Sharma et al. Beneficial effect of antidepressants against rotenone induced Parkinsonism like symptoms in rats
Shawky et al. Levocetirizine ameliorates high fructose diet-induced insulin resistance, vascular dysfunction and hepatic steatosis in rats
WO2017147180A1 (en) Methods for enhancing liver regeneration
Lu et al. Ligustrazine prevents alcohol-induced liver injury by attenuating hepatic steatosis and oxidative stress
Sharawy et al. Anti-fibrotic activity of sitagliptin against concanavalin A-induced hepatic fibrosis. Role of Nrf2 activation/NF-κB inhibition
Arai et al. Acrolein, a highly toxic aldehyde generated under oxidative stress in vivo, aggravates the mouse liver damage after acetaminophen overdose
Bhardwaj et al. Pharmacological induction of hemeoxygenase-1 activity attenuates intracerebroventricular streptozotocin induced neurocognitive deficit and oxidative stress in rats
Antar et al. Coenzyme Q10 mitigates cadmium cardiotoxicity by downregulating NF-κB/NLRP3 inflammasome axis and attenuating oxidative stress in mice
Fouda et al. Exposure to cigarette smoke precipitates simple hepatosteatosis to NASH in high-fat diet fed mice by inducing oxidative stress
Yang et al. Sesamol supplementation alleviates nonalcoholic steatohepatitis and atherosclerosis in high-fat, high carbohydrate and high-cholesterol diet-fed rats
Chen et al. Exogenous hydrogen sulfide ameliorates diabetes-associated cognitive dysfunction by regulating the nrf-2/HO-1 axis and the NLRP3 inflammasome pathway in diabetic rats
CN114007607A (zh) 用于治疗神经变性疾病的材料和方法
Griggs et al. Pharmacologic comparison of clinical neutral endopeptidase inhibitors in a rat model of acute secretory diarrhea
Kwak et al. Aristolochia manshuriensis Kom ethyl acetate extract protects against high-fat diet-induced non-alcoholic steatohepatitis by regulating kinase phosphorylation in mouse
WO2017178630A1 (fr) Utilisation de l&#39;acide fenofibrique dans le traitement des maladies hepatiques
EP4013397A1 (en) Phytocannabinoids for preventing or treating non-alcoholic fatty liver disease, dyslipidemia, and type 2 diabetes
HK40012573B (en) Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver
BR112019004404B1 (pt) Uso de um composto
HK40012573A (en) Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver
Oliveira N-Acetylcysteine (nac): impacts on human health
Cheung-Flynn et al. Reactive Dicarbonyl Scavenging with 2-Hydroxybenzylamine Improves MASH

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

AS Assignment

Owner name: MTI BIOTECH, INC., IOWA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RATHMACHER, JOHN;ABUMRAD, NAJI;FLYNN, CHARLES;REEL/FRAME:051686/0017

Effective date: 20190501

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION